REVENUE MEMORANDUM CIRCULAR NO. 72-2023 issued on June 29, 2023 publishes the May 22, 2023 letter from Food and Drug Administration (FDA) Director General Samuel A. Zacate endorsing updates to the List of VAT-Exempt Medicines under Republic Act No. 11534 (CREATE Act), which now includes certain medicines for cancer, diabetes, high cholesterol, hypertension, kidney disease, mental illness and tuberculosis; corrects medicine for hypertension; and deletes medicine for cancer.
               As clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.